Ixekizumab in Adult Patients With Lichen Planus and Lichen Planopilaris

Inclusion Criteria: * Written informed consent for study participation must be obtained before any study assessment is performed * Male and female patients 18 years or older at the time of screening * Patients who are willing and capable of cooperating to the extent and degree required by the protocol * Patients who read and sign an approved informed consent for this study * Clinical diagnosis of cutaneous lichen planus, lichen planopilaris, frontal fibrosing alopecia at least 6 months prior to enrollment as determined by patient interview of his/her medical history, biopsy proven lichen planus and by confirmation of diagnosis through physical examination by the investigator * Failure to at least one topical treatment (including but not exclusively topical corticosteroids, topical calcineurin inhibitors, topical vitamin D analogues) and/or systemic treatments (including but not exclusively systemic retinoids, griseofulvin, sulfasalazine, hydroxychloroquine, light therapy, methotrexate, etc.) for 4 weeks Exclusion Criteria: * Forms of diagnosed lichen planus other than cutaneous or lichen planopilaris * Previous exposure to ixekizumab or any other biologic drug directly targeting IL-17A or IL-17RA receptors (e.g., secukinumab, brodalumab, etc) * Presence of skin comorbidities that may interfere with study assessments * Plans for administration of live vaccines during the study period or within 6 weeks before randomization * Use of any investigational treatment within 4 week…